On October 10, 2018, The Wall Street Transcript published an interview with Walter Klemp, Chief Executive Officer of Moleculin Biotech, Inc. (Nasdaq: MBRX) as part of its Biotechnology and Pharmaceuticals Special Focus report.
Mr. Klemp provides an overview of Moleculin’s three distinctive technologies and its six oncology drug candidates for the potential treatment of rare and difficult cancers that include: Acute Myeloid Leukemia (AML), glioblastoma – brain tumors, Cutaneous T-Cell Lymphoma (CTCL) – skin cancer and Pancreatic Cancer.
Some of the statements in this interview are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of WP1122 to show safety and efficacy in patients. Although Moleculin Biotech believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this interview speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this interview to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. The Company has purchased the e-Print (PDF) from the Wall Street Transcript (TWST) for the electronic rights to post the interview on its website and distribute the interview electronically (email) with no date of expiration.
52 week Low/High
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.
Lytham Partners, LLC
T: (602) 889-9700
VStock Transfer, LLC
Grant Thornton LLP
Schiff Hardin LLP